ConductScience.org, home

Comparison · NCT02148705-d3391508

NexoBrid Gel vs Gel Vehicle: Primary Endpoint: Number of Participants With Complete Eschar Removal.

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

2 sourcestrial-comparisons-2026-03-23-0.1.0

Download JSON
Cite this record

ConductScience Library. NexoBrid Gel vs Gel Vehicle: Primary Endpoint: Number of Participants With Complete Eschar Removal. Trial comparisons, record NCT02148705-d3391508. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02148705-d3391508

On this page

Measures6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNote
Risk in group 10.9330.8530.971wilson
Risk in group 20.040.00710.195wilson
Risk difference, group 1 minus group 20.8930.7180.943newcombe hybrid score
Risk ratio, group 1 over group 223.33.42159log
Odds ratio, group 1 over group 233637.43,020log
Number needed to treat, for one more participant with the outcome on NexoBrid Gel than on Gel Vehicle1.121.061.39from the risk difference interval

Groups2

Group 2 names the comparator: vehicle.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov code
Group 1NexoBrid GelNexoBrid Gel is applied to the burn wound at a dose of 2 g NexoBrid sterile powder mixed with 20g sterile Gel Vehicle per 1% of TBSA (\~ surface of an adult palm) for four hours.~NexoBrid7075OG000
Group 2Gel VehicleGel Vehicle is applied to the burn wound at a dose of 20 g sterile Gel per 1% of TBSA (\~ surface of an adult palm) for four hours.~Gel Vehicle125OG001

Outcome

Type
PRIMARY
Title
Primary Endpoint: Number of Participants With Complete Eschar Removal.
Description
Comparison of NexoBrid over Gel Vehicle for eschar removal as measured by Number of Participants with complete eschar removal at the end of the topical agent soaking period by a blinded assessor.
Time frame
post application (post 2 h soaking)
Population
Standard of Care (SOC) is not included as it was pre-specified in the statistical analysis plan that for the primary endpoint, NexoBrid Gel will be compared only to the Gel Vehicle

Source ClinicalTrials.gov

Trial

Title
A Study to Evaluate the Efficacy and Safety of NexoBrid in Subjects With Thermal Burns
NCT number
NCT02148705
Phases
PHASE3
Conditions
Thermal Burns
Interventions
NexoBrid, Standard of Care (SOC), Gel Vehicle
Lead sponsor
MediWound Ltd
Results first posted
2023-06-27

Source ClinicalTrials.gov

Source

Release
trial-comparisons-2026-03-23-0.1.0
Release manifest SHA-256
f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
AACT copy
2026-03-23
Tables read
outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet

Source ClinicalTrials.gov

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

For software

Read this comparison from software.

The record is JSON. No key.

GET https://conductscience.org/api/comparisons/v1/NCT02148705-d3391508